These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

690 related items for PubMed ID: 25883123

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.
    Groheux D, Martineau A, Teixeira L, Espié M, de Cremoux P, Bertheau P, Merlet P, Lemarignier C.
    Breast Cancer Res; 2017 Jan 05; 19(1):3. PubMed ID: 28057031
    [Abstract] [Full Text] [Related]

  • 3. Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
    Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G.
    Oncologist; 2020 Apr 05; 25(4):e626-e633. PubMed ID: 32297448
    [Abstract] [Full Text] [Related]

  • 4. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.
    Cancer; 2013 Jun 01; 119(11):1960-8. PubMed ID: 23504954
    [Abstract] [Full Text] [Related]

  • 5. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 6. Role of 18F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy.
    Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, Masumoto N, Okada M.
    Clin Breast Cancer; 2018 Feb 06; 18(1):45-52. PubMed ID: 28993056
    [Abstract] [Full Text] [Related]

  • 7. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment.
    Groheux D, Giacchetti S, Hatt M, Marty M, Vercellino L, de Roquancourt A, Cuvier C, Coussy F, Espié M, Hindié E.
    Br J Cancer; 2013 Sep 03; 109(5):1157-64. PubMed ID: 23942075
    [Abstract] [Full Text] [Related]

  • 8. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F.
    Eur J Nucl Med Mol Imaging; 2014 Aug 03; 41(8):1525-33. PubMed ID: 24647576
    [Abstract] [Full Text] [Related]

  • 9. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer.
    Qu YH, Long N, Ran C, Sun J.
    Clin Transl Oncol; 2021 Mar 03; 23(3):620-627. PubMed ID: 32683540
    [Abstract] [Full Text] [Related]

  • 10. Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer.
    Hatt M, Groheux D, Martineau A, Espié M, Hindié E, Giacchetti S, de Roquancourt A, Visvikis D, Cheze-Le Rest C.
    J Nucl Med; 2013 Mar 03; 54(3):341-9. PubMed ID: 23327900
    [Abstract] [Full Text] [Related]

  • 11. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Breast; 2013 Oct 03; 22(5):691-7. PubMed ID: 23414930
    [Abstract] [Full Text] [Related]

  • 12. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D, Biard L, Giacchetti S, Teixeira L, Hindié E, Cuvier C, Vercellino L, Merlet P, de Roquancourt A, de Cremoux P, Resche-Rigon M, Espié M.
    J Nucl Med; 2016 Apr 03; 57(4):536-43. PubMed ID: 26697967
    [Abstract] [Full Text] [Related]

  • 13. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.
    Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, Lee S, Jung KC, Lee YS, Jeong JM, Lee DS, Chung JK, Moon WK.
    Eur J Nucl Med Mol Imaging; 2014 Aug 03; 41(8):1534-43. PubMed ID: 24652232
    [Abstract] [Full Text] [Related]

  • 14. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M.
    Radiology; 2015 Nov 03; 277(2):358-71. PubMed ID: 25915099
    [Abstract] [Full Text] [Related]

  • 15. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW, Lee HM, Choi SE, Yoo H, Ahn SG, Lee MK, Jeong J, Jung WH.
    J Nucl Med; 2016 Aug 03; 57(8):1183-8. PubMed ID: 27033896
    [Abstract] [Full Text] [Related]

  • 16. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Oncologist; 2017 May 03; 22(5):526-534. PubMed ID: 28377466
    [Abstract] [Full Text] [Related]

  • 17. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M.
    Eur J Cancer; 2014 Jul 03; 50(11):1864-71. PubMed ID: 24841218
    [Abstract] [Full Text] [Related]

  • 18. Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy.
    Lee IH, Lee SJ, Lee J, Jung JH, Park HY, Jeong SY, Lee SW, Chae YS.
    BMC Cancer; 2020 Nov 16; 20(1):1106. PubMed ID: 33198673
    [Abstract] [Full Text] [Related]

  • 19. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
    Lee SH, Ha S, An HJ, Lee JS, Han W, Im SA, Ryu HS, Kim WH, Chang JM, Cho N, Moon WK, Cheon GJ.
    Eur J Nucl Med Mol Imaging; 2016 Aug 16; 43(9):1574-84. PubMed ID: 27209424
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S.
    J Nucl Med; 2013 Nov 16; 54(11):1862-8. PubMed ID: 24092940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.